Transcription inhibition of heat shock proteins: A strategy for combination of 17-allylamino-17-demethoxygeldanamycin andactinomycin d

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3947-3954

  Cervantes Gomez, Fabiola ^a,c   Nimmanapalli, Ramadevi ^d   Gandhi, Varsha ^a,b,c,e  

^a Department of Experimental Therapeutics ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d TUSKEGEE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; MESSENGER RNA; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CELL DEATH; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR CELL LINE; TUMOR RESISTANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CELL LINE, TUMOR; DACTINOMYCIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MULTIPLE MYELOMA; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 65949096108     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4406     Document Type: Article

References (47)

1. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996; 1: 97-8.
2. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571-9.
3. Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L. Mechanisms of disease:the role of heatshock protein 90 in genitourinary malignancy. Nat Clin Pract Urol 2006; 3: 590-601.
4. Blagosklonny MV. Hsp-90-associated oncoproteins:multiple targets of geldanamycin and its analogs. Leukemia 2002; 16: 455-62.
5. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
6. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-7.
7. Stravopodis DJ, Margaritis LH, Voutsinas GE. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 2007; 14: 3122-38.
8. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone:current status. Adv Cancer Res 2006; 95: 323-48.
9. Powers MV, Workman P. Inhibitors of the heat shock response:biology and pharmacology. FEBS Lett 2007; 581: 3758-69.
10. Bagatell R, Whitesell L. Altered Hsp90 function in cancer:a unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-30.
11. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273-9.
12. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002; 7: 277-88.
13. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17- allylamino-17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
14. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006; 13 Suppl 1: S125-35.
15. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17- N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors:a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007; 13: 1783-8.
16. Baler R, Dahl G, Voellmy R. Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Mol Cell Biol 1993; 13: 2486-96.
17. Nadeau K, Das A, Walsh CT. Hsp90 chaperonins possess ATPase activity and bind heat shock transcription factors and peptidyl prolyl isomerases. J Biol Chem 1993; 268: 1479-87.
18. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998; 94: 471-80.
19. Cotto JJ, Kline M, Morimoto RI. Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation. Evidence for a multistep pathway of regulation. J Biol Chem 1996; 271: 3355-8.
20. Wu C. Heat shock transcription factors:structure and regulation. Annu Rev Cell Dev Biol 1995; 11: 441-69.
21. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19: 4310-22.
22. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92: 1564-72.
23. Jaattela M. Escaping cell death:survival proteins in cancer. Exp Cell Res 1999; 248: 30-43.
24. Beere HM. "The stress of dying":the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004; 117: 2641-51.
25. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70:antiapoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-601.
26. Demidenko ZN, Vivo C, Halicka HD, et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin:comparison with caspaseinhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006; 13: 1434-41.
27. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment:in vitro and in vivo study. Cancer Res 2008; 68: 6260-70.
28. Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90 αand βin multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007; 109: 720-8.
29. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17- allylamino-demethoxy geldanamycin. Cancer Res 2005; 65: 10536-44.
30. Rocchi P, Jugpal P, So A, et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006; 98: 1082-9.
31. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14: 250-62.
32. Estlin EJ, Veal GJ. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 2003; 29: 253-73.
33. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci U S A 1985; 82: 5328-31.
34. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines:a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003; 31: 271-82.
35. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986; 46: 5125-30.
36. Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of dactinomycin in a pediatric patient population:a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005; 11: 5893-9.
37. Beliakoff J, Whitesell L. Hsp90:an emerging target for breast cancer therapy. Anticancer Drugs 2004; 15: 651-62.
38. Creagh EM, Sheehan D, Cotter TG. Heat shock proteins-modulators of apoptosis in tumour cells. Leukemia 2000; 14: 1161-73.
39. Chauhan D, Li G, Hideshima T, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102: 3379-86.
40. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2006; 12: 6087-93.
41. Carli M, Pastore G, Perilongo G, et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988; 6: 654-8.
42. Tattersall MH, Sodergren JE, Dengupta SK, Trites DH, Modest EJ, Frei E III. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975; 17: 701-8.
43. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 2006; 20: 601-12.
44. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005; 280: 19166-76.
45. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999; 18: 583-92.
46. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NF-nB pathways and causes potentiation of apoptosis:implications in cancer therapy. Cell Death Differ 2008; 15: 263-73.
47. Hunt C, Morimoto RI. Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70. Proc Natl Acad Sci U S A 1985; 82: 6455-9.